Monday, November 18, 2019
Home News Medical News

Medical News

A major international trial has found that high-risk patients with unstable heart disease can be treated well with medications along rather than invasive procedures such as stents and bypass surgeries. Researchers estimated that this could help save millions of dollars if asymptomatic patients forgo invasive procedures.
A new report has found that new superbugs are a real threat to people because they have become antibiotic-resistant and are killing at least one every 15 minutes. The CDC reported that more than 35,000 have been killed by drug-resistant superbugs. The CDC urged doctors to prescribe antibiotics only when absolutely needed.
A new study has found that a commonly prescribed muscle relaxant called baclofen causes severe confusion and disorientation in patients with chronic kidney dysfunction (CKD). Sold under the brand name Lioresal, baclofen treats muscle pains and cramps. The study was published in JAMA.
Med Man Distribution has voluntarily recalled all lots of a libido supplement called UP2 because the FDA found that it might contain a prescription erectile dysfunction drug, sildenafil. Sildenafil may interact adversely with nitrates and lower the blood pressure to a potentially dangerous level.
A new experimental dengue vaccine has shown some promising results in the ongoing clinical trials. The vaccine, developed by Takeda Pharmaceutical Company, has been found 80 percent effective at preventing the disease in the participants and 95 percent effective at preventing the spread of the disease.
According to a new study, switching to green inhalers could dramatically reduce carbon emissions of carbon footprints and cut down drug costs. The study found that metered-dose inhaler (MDI) contains a potent greenhouse gas that contributes to 4 percent of global carbon emission.
Pfizer, the New York-based pharmaceutical company, has revealed that its profit soared in the third quarter. It said that it gained more than $8 billion by creating a joint venture with GlaxoSmithKline, a key part of its plan to focus more on innovative medications such as Eliquis, Ibrance, and Xeljanz.